Mirum Pharmaceuticals, Inc. (MIRM) company profile
Close on Nov 17, 2026Market cap $5.97BP/E –Yield –
About Mirum Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
This biopharmaceutical company specializes in developing and commercializing therapeutic treatments for rare and orphan diseases with significant unmet medical needs. Its commercial portfolio features three approved prescription medicines: Livmarli, an ileal bile acid transporter inhibitor indicated for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis; Cholbam, formulated for pediatric and adult patients with bile acid synthesis and peroxisomal disorders; and Ctexli, an approved therapy for cerebrotendinous xanthomatosis. The firm also maintains an active clinical pipeline pursuing expanded indications and investigating product candidates for cholestatic liver conditions, chronic viral infections, and neurocognitive disorders. Its therapies primarily serve specialized patient groups managed through medical providers and dedicated healthcare channels.
The company operates globally through direct commercial organizations in the United States, Canada, and select European countries, supplemented by third-party license and distribution partnerships across international territories. In the United States, specific commercial products are distributed via a dedicated specialty pharmacy. The provided text contains no information regarding the company's headquarters location.
Summary of the business section of Mirum Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Mirum Pharmaceuticals, Inc.
- Founded
- 2018
- Headquarters
- Foster City, CA
- Address
- 989 East Hillsdale Boulevard, Suite 300 94404
- Phone
- (650) 667-4085
- Website
- mirumpharma.com
- Employees
- 372, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- MIRM
- Exchange
- Nasdaq
- IPO date
- Jul 18, 2019
- Shares outstanding
- 65M, Jul 31, 2026
- Public float
- $2.30B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1759425
- CUSIP
- 604749101
- ISIN
- US6047491013
- FIGI
- BBG00MH7T2M7
- Share class FIGI
- BBG00MH7T2N6
- LEI
- 254900YZKR40F7F27K81
- EIN
- 83-1281555
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher Peetz | CHIEF EXECUTIVE OFFICER, Director | 394,137 |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 16,728 |
| Robert Paul Myers | Chief Medical Officer | 55 |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 44,745 |
| Peter Radovich | PRESIDENT AND COO | 57,260 |
| Joanne Quan | CHIEF MEDICAL OFFICER | 18,864 |
| Saira Ramasastry | Director | 0 |
| Laura Brege | Director | 15,703 |
| Laurent Fischer | Director | 10,727 |
| Timothy P. Walbert | Director | 9,680 |
| Lon Cardon | Director | 9,680 |
| William Fairey | Director | 2,500 |
| Michael G. Grey | Director | 330,160 |
| Patrick J. Heron | Director | 4,031,625 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $10.44M | $29.65M | $3.49M | $495 | $125 |
| FY2024 | $6.60M | $13.02M | $2.98M | $259 | $93 |
| FY2023 | $6.45M | $9.43M | $3.35M | $185 | $94 |
| FY2022 | $4.40M | $6.50M | $1.53M | $122 | $90 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Christopher Peetz Chief Executive Officer | $755.00K | $3.68M | $4.93M | $1.06M | $14.00K | $10.44M | +58% |
| Eric Bjerkholt Chief Financial Officer | $520.00K | $959.60K | $1.28M | $468.00K | $14.00K | $3.25M | +62% |
| Peter Radovich President and Chief Operating Officer | $572.50K | $1.20M | $1.61M | $572.50K | $14.00K | $3.96M | +19% |
| Joanne Quan, M.D. Chief Medical Officer | $520.00K | $959.60K | $1.28M | $468.00K | $14.00K | $3.25M | -10% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 18, 2019
- Offer price
- $15.00
- Securities offered
- 5,000,000
- Gross proceeds
- $75.00M
- Exchange
- Nasdaq
- First trading day
- Jul 18, 2019
- First-day close
- $13.21-11.9%
- Lock-up ends (est.)
- Jan 14, 2020
“The initial public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 372 employees, of whom 369 are full time, consisting of clinical, research, operations, finance and business development personnel.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 26, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 28, 2024 | Late filing | Notification of late filing |
| Sep 5, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 22, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 18, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 15, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?